scorecardresearch
Add as a preferred source on Google
Friday, January 23, 2026
TopicBig Pharma

Topic: Big Pharma

Big pharma pivoting to more lucrative obesity segment, Indian drugmakers eye insulin market

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady entry into a market once dominated by Big pharma.

‘Can hamper entry of new drugs’ — groups raise alarm over IP proposals part of India-EFTA talks

India & EFTA (Iceland, Liechtenstein, Norway and Switzerland) are negotiating Trade and Economic Partnership Agreement (TEPA) that is likely to be finalized within next few weeks.

Novartis, Eli Lilly oppose compulsory licences for breast cancer drugs, say sales up despite price

Pharma giants were responding to petition in Kerala HC seeking compulsory licences for their HER2-negative breast cancer drugs, which would allow cheaper, generic versions to be made.

India banks on Hyderabad’s ‘Pharma City’ to break China’s stranglehold over drug supplies

India’s $42 billion drug manufacturing industry relies intensely on China, which supplies almost 70% of the active pharmaceutical ingredients that go into making medicines.

Who’s responsible if vaccines go wrong? Pharma companies or govts? There are no easy answers

Given the speed of vaccine production, there are few answers for what Pharma companies & govts are ultimately responsible for.

Covid pandemic gives businesses plenty of reasons to get back to dealmaking

It was the pharma industry that kicked off the global megamerger wave last time around, in early 2014.

Big pharma is looking beyond coronavirus with AstraZeneca eyeing merger with Gilead

The suggestion of a blockbuster merger between the two drugmakers is a sign that the industry is getting back to something resembling business as usual.

Big Pharma has failed. It’s been 35 years since a new class of antibiotics entered the market

Antibiotics are among the most important medicines known to humankind, but we are running out of it.

Lucrative drugs like Viagra, Humira to lose patents but Indian pharma unlikely to gain

Indian pharma companies, which have dominated the world’s generic medicines market, are now hampered by Trump’s policies & lack of expertise in biologics.

How Ranbaxy faked manufacturing data for all drugs not only in India, but in US, Europe too

Ranbaxy was treating data as an entirely fungible marketing tool, apparently without consideration of impact on patients. It was an outright fraud.

On Camera

Controversial dog-walker IAS Sanjeev Khirwar is back in Delhi. What happened to his wife?

In 2022, athletes claimed they were asked to wind up training early at Thyagraj Stadium so that the IAS couple could walk their dog. Then came the memes and public outrage.

IndiGo profit plunges 78% as Dec meltdown with 3k flight cancellations takes a toll

Net income for InterGlobe Aviation Ltd slipped 78 percent to Rs 5.5 billion for the three months ended Dec 31 compared with the year-ago period.

Rafale saga: 25 yrs of detours, deadlocks & political hesitation. Now IAF getting what it always wanted

Instead of buying more Mirages outright in early 2000s, the requirement was tweaked in favour of a medium-weight, multi-role fighter with Mirage-like performance. 

Pakistan se azaadi. Grow up India, stop giving it prime real estate in your psyche

Pakistan not only has zero chance of catching up with India in most areas, but will inevitably see the gap rising. Its leaders will offer its people the same snake oil in different bottles.